Ying En Biotech-B (09606) key product DB-1310 obtained the US FDA designation for fast track qualification.

Intelligence Finance APP News, Ying en Bio-B (09606) announced that the company's key product DB-1310 (an antibody-conjugated drug (ADC) targeting human epidermal growth factor receptor 3 (HER3)) has been granted fast track designation by the US Food and Drug Administration (FDA) for the treatment of advanced/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC) in adult patients who have disease progression during or after treatment with third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy, and who carry EGFR exon 19 deletions or L858R mutations.